09Sep 2023
Maternal Hypertension and Neonatal Unit Admissions: Identifying Opportunities for Prevention and Care

Maternal Hypertension and Neonatal Unit Admissions: Identifying Opportunities for Prevention and Care

The FDA has approved generic Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets. These generics are designed to assist individuals aged six and older with attention-deficit/hyperactivity disorder (ADHD) and adults facing moderate to severe binge-eating disorder (BED). ADHD, a common neurodevelopmental disorder affecting approximately 10% of children, often persists into adulthood. The newly approved generics offer the same clinical benefits and risks as the branded counterparts. However, healthcare professionals and patients should be aware of potential abuse and dependency risks associated with these medications, as they can affect specific brain chemicals and may lead to addiction and overdose. The FDA has also mandated labeling updates for prescription stimulants to communicate these risks effectively.

  • #family health

Like

Save

Share